London, United Kingdom
Flarin, a United Kingdom-based company founded in 2000, has carved a distinct niche in the Health Care and Pharmaceutical industries with its innovative product, an OTC lipid-formulated ibuprofen branded as "Highly Effective Joint Pain Relief, Unique Lipid Formulation."
This product is notable for its potential to rival prescription-strength ibuprofen due to its unique formulation, offering effective relief for joint pain and inflammation associated with rheumatic, muscular, and non-serious arthritic conditions. A clinical study involving 462 patients further substantiates its efficacy in controlling flare-ups.
Commercially, Flarin enhances consumer accessibility by packaging its product in 30 and 12 soft capsules, backed by infirst Ltd's patented technologies. Recently, the company secured a significant £5.00M venture round investment on 15 August 2023, led by IW Capital and ITV AdVentures, underscoring investor confidence in its market potential.
